Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 6, 2006, Pages 642-653

  Marier, Jean Francois ^a   Lor, Mary ^a   Potvin, Diane ^a   DiMarco, Marika ^a   Morelli, Gaetano ^a   Sædder, Eva Aggerholm ^b  

^a MDS Inc   (Canada)

^b Nycomed Denmark   (Denmark)

Author keywords

Fentanyl; Matrix transdermal delivery system; Pharmacokinetics; Tolerability

Indexed keywords

FENTANYL; NALOXONE; NALTREXONE; PROPYLENE GLYCOL; SILICONE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; EAR DISEASE; EYE DISEASE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HUMAN EXPERIMENT; INFECTION; INFESTATION; INJECTION SITE REACTION; INNER EAR DISEASE; KIDNEY DISEASE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; NUTRITIONAL DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SKIN IRRITATION; THORAX DISEASE; URINARY TRACT DISEASE;

ADMINISTRATION, CUTANEOUS; ADULT; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; FENTANYL; HUMANS; MALE; MIDDLE AGED;

EID: 33745278000     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006286901     Document Type: Article

References (28)

1. Kornick CA, Santiago-Palma J, Moryl N, Payne R, Obbens EA. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf. 2003;26:951-973.
2. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53:109-138.
3. Fiset P, Cohane C, Browne S, Brand SC, Shafer SL. Biopharmaceutics of a new transdermal fentanyl device. Anesthesiology. 1995;83:459-469.
4. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 2000;38:59-89.
5. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg. 1996;82:167-172.
6. Plezia PM, Kramer TH, Linford J, Hameroff SR. Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy. 1989;9:2-9.
7. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos. 1997;25:1072-1080.
8. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989;70:928-934.
9. Roy SD, Gutierrez M, Flynn GL, Cleary GW. Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J Pharm Sci. 1996;85:491-495.
10. Gupta SK, Southam M, Gale R, Hwang SS. System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Manage. 1992;7(suppl 3):S17-S26.
11. Berner B, John VA. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet. 1994;26:121-134.
12. Ranade VV. Drug delivery systems. 6. Transdermal drug delivery. J Clin Pharmacol. 1991;31:401-418.
13. US Food and Drug Administration. Center for Drug Evaluation and Research, Alert for Healthcare Professionals Fentanyl Transdermal System (marketed as Duragesic). Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/drug/ InfoSheets/HCP/fentanylHCP.htm.
14. US Food and Drug Administration. Safety Alerts for Drugs, Biologies, Medical Devices, and Dietary Supplements. Food and Drug Administration Web site. Available at: http://www.fda.gov/ medwatch/safety.htm.
15. Freynhagen R, von Giesen HJ, Busche P, Sabatowski R, Konrad C, Grond S. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage. 2005;30:289-297.
16. Tan HS, Pfister WR. Pressure-sensitive adhesives for transdermal drug delivery systems. Pharm Sci Technol Today. 1999;2:60-69.
17. World Medical Association Declaration of Helsinki. Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. Ferney-Voltaire, France: World Medical Association Declaration of Helsinki; 1996.
18. US Department of Health and Human Services, ed. Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products. Rockville, MD: Food and Drug Administration Center for Drug Evaluation and Research; 1999.
19. Lambropoulos J, Spanos GA, Lazaridis NV, Igallinera TS, Rodriguez VK. Development and validation of an HPLC assay for fentanyl and related substances in fentanyl citrate injection, USP. J Pharm Biomed Anal. 1999;20:705-716.
20. Rowland M, Towzer TN. "Metabolite kinetics". In: Clinical Pharmacokinetics: Concepts and Application, 3rd ed. Media, PA: Lippincott Williams & Wilkins; 1995: 367-393.
21. Solassol I, Bressolle F, Caumette L, Garcia F, Poujol S, Culine S, et al. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit. 2005;27:491-498.
22. Gourlay GK. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol. 2001;2:165-172.
23. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001;61:2289-2307.
24. Sitruk-Ware R. Transdermal application of steroid hormones for contraception. J Steroid Biochem Mol Biol. 1995;53:247-251.
25. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63:2011-2012.
26. Auclair B, Sirois G, Ngoc AH, Ducharme MP. Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. Ther Drug Monit. 1998;20:607-611.
27. Kaiko RF, Grandy RP, Reder RF, Goldenheim PD, Sackler RS. A bioequivalence study of oral controlled-release morphine using naltrexone blockade. J Clin Pharmacol 1995;35:499-504.
28. Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother. 1995;29:969-971.